7 completed. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 7 |
Follow Relapsing Multiple Sclerosis: new trials by email Literature Review of Relapsing Multiple Sclerosis trials Research Report on Relapsing Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China Ofatumumab - Relapsing Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 99 | 2022-07-22 | 2026-01-13 |
| Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab Ofatumumab - Relapsing Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 34 | 2021-05-27 | 2025-05-16 |
| A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab Quadrivalent influenza vaccine, Ofatumumab, iDMT - Relapsing Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 63 | 2021-01-14 | 2024-10-09 |
| To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis TERIFLUNOMIDE HMR1726 - Relapsing Multiple Sclerosis | Phase 4 | Completed | Sanofi | 121 | 2019-03-27 | 2023-04-19 |
| A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod Fingolimod - Relapsing Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 382 | 2017-09-19 | 2021-10-07 |
| Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ Rebif - Relapsing Multiple Sclerosis, Clinically Isolated Syndrome | Phase 4 | Completed | Merck KGaA, Darmstadt, Germany | 106 | 2014-12-31 | 2018-03-30 |
| The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial Blood sampling - Relapsing Multiple Sclerosis | Phase 4 | Completed | EMD Serono | 324 | 2010-02-01 | 2014-03-10 |
Multiple Sclerosis (2) · COVID-19 (1)
Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Demyelinating Diseases (2) · Immune System Diseases (2) · Nervous System Diseases (2) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Infections (1) · Lung Diseases (1) · Nidovirales Infections (1) · Pneumonia (1) · Pneumonia, Viral (1) · RNA Virus Infections (1) · Respiratory Tract Diseases (1)
ofatumumab (3) · Blood Specimen Collection (1) · Fingolimod Hydrochloride (1) · Influenza Vaccines (1) · Interferon beta-1a (1) · teriflunomide (1)
Novartis Pharmaceuticals (4) · EMD Serono (1) · Merck KGaA, Darmstadt, Germany (1) · Sanofi (1)
United States (3) · Germany (2) · China (1) · India (1)
Elisabetta Verdun di Cantogno, MD (1)
2014 (1)